These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
554 related articles for article (PubMed ID: 8096092)
1. [Local or systemic treatment of inflammatory bowel diseases?]. Schmassmann A; Halter F Ther Umsch; 1993 Feb; 50(2):94-9. PubMed ID: 8096092 [TBL] [Abstract][Full Text] [Related]
2. [Conservative therapy of ulcerative colitis and Crohn disease]. Rasenack J; Kreisel W Fortschr Med; 1991 Apr; 109(11):245-7. PubMed ID: 1855750 [TBL] [Abstract][Full Text] [Related]
3. [Drug therapy of chronic inflammatory bowel disease--reliable standards and new developments]. Fischbach W Leber Magen Darm; 1992 Mar; 22(2):49-55. PubMed ID: 1350043 [TBL] [Abstract][Full Text] [Related]
4. Medical management of patients with difficult-to-treat inflammatory bowel disease. van Hogezand RA Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006 [TBL] [Abstract][Full Text] [Related]
5. Current status of drug therapy for inflammatory bowel disease. Peppercorn MA Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866 [TBL] [Abstract][Full Text] [Related]
6. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease. Segars LW; Gales BJ Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685 [TBL] [Abstract][Full Text] [Related]
7. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)]. Maier K; Fischer C; Klotz U; Heinkel K Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426 [TBL] [Abstract][Full Text] [Related]
8. Medical therapy for ulcerative colitis in childhood. Ament ME; Vargas JH Semin Pediatr Surg; 1994 Feb; 3(1):28-32. PubMed ID: 7914811 [TBL] [Abstract][Full Text] [Related]
11. [Drug therapy of ulcerative colitis]. Rückert Y Z Arztl Fortbild Qualitatssich; 1997 Mar; 91(2):175-9. PubMed ID: 9244661 [TBL] [Abstract][Full Text] [Related]
12. [Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid]. Schölmerich J; Gerok W Wien Klin Wochenschr; 1986 Nov; 98(22):762-9. PubMed ID: 2880425 [TBL] [Abstract][Full Text] [Related]
13. Medical treatment of inflammatory bowel disease: new therapies, new drugs. Sutherland LR CMAJ; 1987 Nov; 137(9):799-802. PubMed ID: 2894889 [TBL] [Abstract][Full Text] [Related]
14. [Drug treatment of chronic inflammatory bowel diseases: current status and prospects]. Seibold F; Wagner AC; Göke B Schweiz Med Wochenschr; 2000 Feb; 130(7):222-32. PubMed ID: 10719713 [TBL] [Abstract][Full Text] [Related]
16. Topical salicylate therapy (4-ASA and 5-ASA enemas). Ginsberg AL Gastroenterol Clin North Am; 1989 Mar; 18(1):35-42. PubMed ID: 2563990 [TBL] [Abstract][Full Text] [Related]
17. [Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease]. Bayerdörffer E; Bock H Leber Magen Darm; 1988 Apr; 18(2):104-13. PubMed ID: 3374251 [TBL] [Abstract][Full Text] [Related]
18. Sulfasalazine and 5-ASA compounds. Allgayer H Gastroenterol Clin North Am; 1992 Sep; 21(3):643-58. PubMed ID: 1355468 [TBL] [Abstract][Full Text] [Related]
19. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Marshall JK; Irvine EJ Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961 [TBL] [Abstract][Full Text] [Related]